{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T22:59:31Z","timestamp":1657321171266},"reference-count":14,"publisher":"ALUNA","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>The aim: To determine efficacy and safety of allopurinol and febuxostat in treatment of patients with CKD to reduce the sUA level and analyze its influence on glomerular filtration rate (GFR). \nMaterials and methods: The study included 45 CKD patients (stages 3b-5) without other severe\/decompensated diseases and contraindications to the allopurinol\/febuxostat. All patients underwent a comprehensive clinical and laboratory examination, and were divided into the study groups: Group I (28 patients, 61,3\u00b13,2 y.o., CKD3b-12, CKD4-10, on hemodialysis-6 patients) received febuxostat, Group II (24 patients, 60,7\u00b14,1y.o., CKD3b-9, CKD4-10, on hemodialysis -5 patients) took allopurinol. \nResults: Achievement of the target level of sUA was significantly often registered in Group I: after 1 month \u2013 in 45.5% (in group II \u2013 in 15.9%, p&lt;0.001); after 3 months \u2013 in 67.5% (in group II \u2013 21.2% p&lt;0.01); after 6 months, these figures were 90% and 37.1%, respectively (p&lt;0.01). sUA level &lt;300 \u03bcmol\/l was accompanied by significant positive GFR changes in group I patients; in group II there was a gradual progression of GFR deterioration in 31.8% of patients. \nConclusions: In patients with pre-dialysis stages of CKD febuxostat demonstrates renoprotective abilities. Use of febuxostat in patients with CKD stage 3b-4 and in patients on hemodialysis is safe and more effective for target sUA level achievement than the use of allopurinol.<\/jats:p>","DOI":"10.36740\/wlek202205102","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T15:35:19Z","timestamp":1656344119000},"page":"1059-1063","source":"Crossref","is-referenced-by-count":0,"title":["POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA"],"prefix":"10.36740","volume":"75","author":[{"given":"Liudmyla V.","family":"Khimion","sequence":"first","affiliation":[{"name":"SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE; KNP KOR KYIV REGIONAL CLINICAL HOSPITAL, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr A.","family":"Burianov","sequence":"additional","affiliation":[{"name":"BOGOMOLETS NATIONAL MEDICAL UNIVERSITY, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna M.","family":"Nayshtetik","sequence":"additional","affiliation":[{"name":"CLINIC OF MODERN RHEUMATOLOGY, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svitlana O.","family":"Rotova","sequence":"additional","affiliation":[{"name":"SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svitlana I.","family":"Smiyan","sequence":"additional","affiliation":[{"name":"I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svitlana V.","family":"Danyliuk","sequence":"additional","affiliation":[{"name":"SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE; KNP KOR KYIV REGIONAL CLINICAL HOSPITAL, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoriia V.","family":"Trofanchuk","sequence":"additional","affiliation":[{"name":"KNP KOR KYIV REGIONAL CLINICAL HOSPITAL, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref0","unstructured":"1. Chronic kidney disease in US, 2021. https:\/\/www.cdc.gov\/kidneydisease\/ pdf\/Chronic-Kidney-Disease-in-the-US-202 [date access 12.12.2021]."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Kuma A., Mafune K., Uchino B. et al. Alteration of normal level of serum urate may contribute to decrease in estimated glomerular filtration rate decline in healthy Japanese men. Ren Fail. 2021;43(1):1408-1415. doi: 10.1089\/0886022X.2021.1988969.","DOI":"10.1080\/0886022x.2021.1988969"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Capuano V., Marchese F., Capuano R. et al. Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med. 2017;18:159-164.","DOI":"10.2459\/jcm.0000000000000347"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Li L., Yang C., Zhao Y. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analyse based on observational cohort studies. BMC Nephrol. 2014;15:122.","DOI":"10.1186\/1471-2369-15-122"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Sharma G., Dubey A., Nolkha N. et al. Hyperuricemia, urate-lowering therapy, and kidney outcomes; a systematic review and meta-analysis. Ther Adv Musculoscelet Dis. 2021;13:1-21.","DOI":"10.2139\/ssrn.3279190"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Yu P., Huang Li., Wang Z. et al. The association of serum uric acid with beta-cell function and insulin resistance in non-diabetic individuals: a cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:2673-2682.","DOI":"10.2147\/dmso.s312489"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Usama A. A., Sharaf E. D., Salem M. M. et al. Uric acid in the pathogenesis of metabolic, renal and cardiovascular diseases; a review. J of Adv Res. 2017;8(5):537-548.","DOI":"10.1016\/j.jare.2016.11.004"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Obermayr R. P., Temml C., Gutjahr G. et al. Elevated uric acid increases the risk for kidney disease. JASN. 2008;19(12):2407\u20132413.","DOI":"10.1681\/asn.2008010080"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Weiner D. E., Tighiouart H., Elsayed E. F. et al. Uric acid and incident of kidney disease in community. JASN. 2008;19(6):1204\u20131211.","DOI":"10.1681\/asn.2007101075"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Skoczynska M., Chowaniec M., Szymczak A. et al. Pathophysiology of hyperuricemia and its clinical significance \u2013 a narrative review. 2020;58(5):312-323.","DOI":"10.5114\/reum.2020.100140"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Badve S. V., Pascoe E. M., Biostat M. et al. Effects of allopurinol on the Progression of Chronic Kidney Disease. N Eng J Med. 2020;382:2504- 2513.","DOI":"10.1056\/NEJMoa1915833"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Liu X., Liu K., Sun Q. et al. Efficacy and safety of febuxostat for treating hyperuricemia in patients with CKD and renal transplant recipients: a systemic review and meta-analysis. Exp Ther Med. 2018;16(3):1859- 1865. doi:10.3892\/etm.2018.6367.","DOI":"10.3892\/etm.2018.6367"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Lin T. C., Hung L. Y., Chen Y-C. et al. Effects of febuxostat on renal function in patients with chronic kidney disease. A systematic review and meta-analysis. Medicine. 2019;98:29(e16311).","DOI":"10.1097\/md.0000000000016311"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Keilstein J. T., Pontremoli R., Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep. 2020;22:102.","DOI":"10.1007\/s11906-020-01116-3"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T15:35:24Z","timestamp":1656344124000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2022\/05\/WLek202205102.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":14,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022]]},"published-print":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202205102","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}